If Massachusetts is the New England innovation economy’s Goliath (and we’d argue that it is), Rhode Island is David. And the state has a new weapon in hand as it goes up against its much larger neighbor: a targeted tax credit of up to $100,000. Rhode Island hopes the credit will encourage investment in its … Continue reading “First Rhode Island Startups Closing in on Tax Credit Under New Stimulus Program”
Author: Henry Johnson
Perceived Risk, Culture Clash Did in Biogen Idec Sale, CEO Asserts
Pharmaceutical suitors shied away from buying Cambridge, MA-based Biogen Idec (NASDAQ:[[ticker:BIIB]]) last fall because they were too afraid of the risks associated with acquiring a biotech, Biogen CEO James Mullen said in today’s Boston Globe. In San Francisco for this week’s JPMorgan investor conference, Mullen said that pharmaceutical companies are in general much more cautious … Continue reading “Perceived Risk, Culture Clash Did in Biogen Idec Sale, CEO Asserts”
Cynosure Claims Patent Infringement Against Rival Cosmetic Laser Company
Cynosure, a Westford, MA-based cosmetic laser company, (NASDAQ: [[ticker:CYNO]]) and its largest shareholder are suing a California rival for allegedly infringing on a patent for a liposuction tool. Cynosure and El.En. of Firenze, Italy, allege that CoolTouch of Roseville, CA, violated their patent for using laser energy to remove subcutaneous fat. The lawsuit was filed … Continue reading “Cynosure Claims Patent Infringement Against Rival Cosmetic Laser Company”
ACT Creates Stem Cells, Spares Embryos
Advanced Cell Technology, a Los Angeles, CA-based stem cell company with research operations in Worcester, MA, announced on Thursday that it’s been able to derive five stem cell lines from human embryos without destroying the embryos. The company’s approach (OTC BB: [[ticker:ACTC]]) was published in the new edition of the journal Cell Stem Cells, published … Continue reading “ACT Creates Stem Cells, Spares Embryos”
Avant to Appeal NASDAQ Delisting Decision
Avant Immunotherapeutics, a Needham, MA-based vaccine developer, announced on Wednesday that it is appealing a delisting notice from the NASDAQ market. Avant (NASDAQ:[[ticker:AVAN]]) was told by the stock exchange on January 8 that it would be delisted on January 17 for failing to boost its share price to at least $1 per share. The company’s … Continue reading “Avant to Appeal NASDAQ Delisting Decision”